← Back to Clinical Trials
Recruiting Phase 4 NCT06826339

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

Trial Parameters

Condition Venous Leg Ulcer
Sponsor Tiger Biosciences, LLC.
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 340
Sex ALL
Min Age 21 Years
Max Age N/A
Start Date 2024-12-06
Completion 2027-12
Interventions
ACApatch™caregraFT™Standard of Care

Brief Summary

Title A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform (Matriarch) Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care versus Standard of Care alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

Eligibility Criteria

Inclusion Criteria:(DFU) * Subjects The potential subject must be at least 21 years of age or older. * The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus. * At enrollment, the potential subject must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement. * The potential subject must have a target ulcer that has been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit. * The potential subject must have a target ulcer located on the foot with at least 50% of the ulcer below the malleolus. * The potential subject must have a target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. * The potential subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following m

Related Trials